MediciNova, Inc., a biopharmaceutical company, announced the completion of target enrollment in its COMBAT-ALS Phase 2b/3 clinical trial for its lead compound MN-166 (ibudilast), which is under development for the treatment of Amyotrophic Lateral Sclerosis (ALS). The company highlighted that this milestone is significant for ALS research. The results of the trial will be presented in the future, as the trial is among the most advanced in the field. Additionally, MediciNova is conducting a large Expanded Access Program supported by a $22 million NIH grant and is nearing completion of patient enrollment in a Phase 2 clinical trial for hypertriglyceridemia and fatty liver disease due to Type 2 diabetes with its second asset, MN-001 (Tipelukast). The company also secured a Standby Equity Purchase Agreement for up to $30 million, providing flexibility to support its ongoing R&D and corporate initiatives.